Anti Tnf Therapy
Anti Tnf Therapy - Related Videos
16:07
Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
0 Views •
Cited by 1 •
2017
A protocol for the determination of the relative anti-apoptotic activity of an anti-TNFα mAb using a neutralization mechanism with WEHI 164 cells is presented here. This protocol is useful for comparing the neutralization strength of different molecules with the same biological functionality.
01:24
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
0 Views •
2024
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
09:29
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
0 Views •
Cited by 23 •
2016
Utilizing patient-derived tumors in a subcutaneous preclinical model is an excellent way to study the efficacy of novel therapies, predictive biomarker discovery, and drug resistant pathways. This model, in the drug development process, is essential in determining the fate of many novel anti-cancer therapies prior to clinical investigation.
08:27
Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
0 Views •
Cited by 4 •
2018
Dynamic adhesion of immune cells to the vessel wall is a prerequisite for gut homing. Here, we present a protocol for a functional in vitro assay for the impact analysis of anti-integrin antibodies, chemokines or other factors on the dynamic cell adhesion of human cells using addressin-coated capillaries.
10:15
Isolation and Characterization of Neutrophils with Anti-Tumor Properties
0 Views •
Cited by 46 •
2015
Neutrophils play an important role not only in host defense against invading microorganisms, but are also involved in the immune surveillance of tumor cells. Here, we describe techniques related to the isolation of neutrophils with anti-tumor properties and methods for monitoring anti-tumor neutrophil function in vitro and in vivo.
FAQs
Monoclonal antibodies act by binding tumor necrosis factor directly, whereas receptor fusion proteins block TNF from interacting with cell-surface receptors. Both approaches reduce the cytokine signal that promotes inflammation, but they intervene through different molecular components. This distinction illustrates how biologic medicines can target the same inflammatory pathway using different molecular designs.
TNF coordinates immune responses and can contribute to tissue injury when its inflammatory signaling remains active. Anti-TNF agents limit this activity by preventing TNF from engaging its relevant cell-surface receptors or by binding the cytokine itself. Reduced downstream signaling can therefore lessen inflammation and help control disease activity in immune-mediated disorders.
Selective cytokine inhibition demonstrates how pharmacology can modify a defined component of an immune response rather than suppressing inflammation without a specific target. By focusing on TNF, anti-TNF therapy connects molecular mechanism with clinical control of inflammatory disease. Its effects also show why immune pathway blockade requires attention to infection and other immune-related adverse effects.
Anti-TNF therapy is used for several immune-mediated disorders, including rheumatoid arthritis, inflammatory bowel disease, and psoriasis. These conditions differ clinically, yet each can involve inflammatory activity that responds to TNF pathway inhibition. The range of indications shows that one targeted cytokine mechanism can have therapeutic relevance across multiple disease settings.
Treatment requires monitoring for infections, injection reactions, and other immune-related adverse effects. These checks are important because altering TNF-mediated immune signaling can affect more than the intended inflammatory pathway. In pharmacology, monitoring links the desired outcome of reduced disease activity with assessment of tolerability and potential complications during therapy.
Researchers can evaluate whether treatment controls disease activity while also tracking immune-related safety findings. Relevant observations include the therapeutic reduction of inflammation, evidence of infection, injection reactions, and other adverse effects. Together, these outcomes help characterize both the clinical benefit and the consequences of selectively blocking TNF signaling in immune-mediated disorders.